Stuart Pocock REFERENCE: ABSTRACT N Engl J Med 2007; 357: 28-381 STUART POCOCK, London School of Hygiene and Tropical Medicine Reassuring findings about the safety of the anti-diabetic drug rosiglitaz
Stuart Pocock
REFERENCE: ABSTRACT N Engl J Med 2007;357: 28-381STUART POCOCK, London School of Hygiene and Tropical MedicineReassuring findings about the safety of the anti-diabetic drug rosiglitazone have been published in the New England Journal of Medicine following an interim analysis of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) study. This latest publication follows a meta-analysis in June 2007 by Nissen and Wolski which raised doubt about the safety of the drug. Nicola Solomon spoke with the RECORD trial’s statistician,Stuart Pocock, to get the latest data from this largest study specifically designed to look at cardiovascular outcomes.
Tags
Related Episodes
Healthcare Delivery And Spending: Big Impact On Cancer Survival
LONDON—Inequalities in cancer care delivery and overall spending have had a big impact on cancer survival rates in Europe, according to Michel Coleman, Professor of Epidemiology and Vital Statistics a
Murder And Suicide: Study Finds Link With Economic Crises, Unemployment
David Stuckler of Oxford University and the London School of Hygiene and Tropical Medicine tells Peter Goodwin about the findings of his study, just published in the Lancet, showing that increasing ec
London School of Hygiene & Tropical Medicine Audio News
Andy Haines Peter Goodwin and Sarah Maxwell take part in the discussions held in London on the controversial role of the corporate sector in tackling the looming threat to global health of obesity aro